339 related articles for article (PubMed ID: 25412233)
1. Unlocking the potential of retinoic acid in anticancer therapy.
Schenk T; Stengel S; Zelent A
Br J Cancer; 2014 Nov; 111(11):2039-45. PubMed ID: 25412233
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
3. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Apr; 10 Suppl 1():S12-5. PubMed ID: 8618462
[TBL] [Abstract][Full Text] [Related]
4. The success and the challenge of all-trans retinoic acid in the treatment of cancer.
Ni X; Hu G; Cai X
Crit Rev Food Sci Nutr; 2019; 59(sup1):S71-S80. PubMed ID: 30277803
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
6. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
7. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond.
Tallman MS
Leukemia; 1998 Sep; 12 Suppl 1():S37-40. PubMed ID: 9777894
[TBL] [Abstract][Full Text] [Related]
8. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
10. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship.
Agadir A; Cornic M; Lefebvre P; Gourmel B; Jérôme M; Degos L; Fenaux P; Chomienne C
J Clin Oncol; 1995 Oct; 13(10):2517-23. PubMed ID: 7595702
[TBL] [Abstract][Full Text] [Related]
11. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.
Su M; Alonso S; Jones JW; Yu J; Kane MA; Jones RJ; Ghiaur G
PLoS One; 2015; 10(6):e0127790. PubMed ID: 26047326
[TBL] [Abstract][Full Text] [Related]
12. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
[TBL] [Abstract][Full Text] [Related]
13. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
Burry LD; Seki JT
Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
[TBL] [Abstract][Full Text] [Related]
14. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
15. Differentiation therapy of acute myeloid leukemia: past, present and future.
Petrie K; Zelent A; Waxman S
Curr Opin Hematol; 2009 Mar; 16(2):84-91. PubMed ID: 19468269
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S
Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859
[TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.
van Gils N; Verhagen HJMP; Smit L
Exp Hematol; 2017 Aug; 52():12-23. PubMed ID: 28456748
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
[TBL] [Abstract][Full Text] [Related]
20. [Clinical pharmacology of all-trans retinoic acid (ATRA)].
Robak T
Acta Haematol Pol; 1995; 26(3):269-77. PubMed ID: 8525772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
